TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04509622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous Injection
Study: NCT01534897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
Study: NCT01509053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (Abilify®) IM Depot Injection
Description: 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole
Description: Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
Study: NCT00388193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RITUXIMAB
Description: 375 mg/m2/d day 1
Study: NCT03279640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS on ipsilesional M1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS on ipsilesional M1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS on contralesional M1
Study: NCT02906605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-809
Description: JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg orally daily.
Study: NCT02233413

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active LLLT helmet application
Description: LED helmet applied without light activated
Study: NCT00587457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 5 mcg/kg
Description: Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 10 mcg/kg
Description: Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 20 mcg/kg
Description: Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study: NCT01259999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calogen extra strawberry
Description: A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
Study: NCT00008697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study: NCT00620529

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocean Nutrition 2050
Description: 1000mg capsules, 4 capsules/day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil capsules
Description: Olive oil capsules, 4 per day for 8 weeks
Study: NCT02842190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: after ekstubation
Study: NCT04138017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViviGen
Description: A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
Study: NCT00895713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular hepatitis B virus immune globulin
Description: Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
Study: NCT01644929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
Study: NCT01644929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham stimulation, then tDCS
Description: Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation for 30 seconds on 15 days during 6 weeks
Study: NCT01616693

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral polio vaccine
Description: A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral polio vaccine
Description: A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine
Description: A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
Study: NCT03739021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
Study: NCT03881787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR monoclonal antibody
Description: Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab injection
Description: Cetuximab injection
Study: NCT03653741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 6 MG
Description: Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
Study: NCT03219580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: 0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
Study: NCT00564980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wafer Procedure
Description: A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar shortening osteotomy
Description: A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
Study: NCT00964704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: background therapy at time of disease progression, 100mg/m2 iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
Study: NCT03118882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet group
Description: A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity group
Description: A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and diet group
Description: A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
Study: NCT03628326

Intervention type: OTHER
Intervention: Pulmonary arterial tree
Description: The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.

Intervention type: OTHER
Intervention: Pulmonary arterial tree
Description: The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
Study: NCT04377867

Intervention type: DRUG
Intervention: Abatacept Injection [Orencia]
Description: Patients on abatacept to control disease symptoms

Intervention type: DRUG
Intervention: Abatacept Injection [Orencia]
Description: Patients on abatacept to control disease symptoms
Study: NCT03739021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
Study: NCT03337412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity
Description: Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire
Study: NCT04320537

Intervention type: OTHER
Intervention: abstinence from use of marijuana and other abused drugs
Description: abstinence from use of marijuana use and other abused drugs

Intervention type: OTHER
Intervention: abstinence from use of marijuana and other abused drugs
Description: abstinence from use of marijuana use and other abused drugs
Study: NCT03138681

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo is given intravenously twice a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP
Description: ATP (100mg) is given intravenously twice a day for 14 days
Study: NCT03951350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program (LMP)
Description: Patients will follow TAU and LMP. This program will consist of 6 weekly group sessions (lasting 90 minutes each) led by an experienced psychologist and complemented by PowerPoint presentations. The content is the following:~1. Presentation of the project and psychoeducation on depression.~2. Behavior activation.~3. Sleep hygiene habits and careful exposure to sunlight.~4. Physical activity.~5. Adherence to the Mediterranean diet.~6. Summary of previous sessions with practical final suggestions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)
Description: Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification Program (LMP) + Information Communication Technologies (ICTs)
Description: Patients will follow TAU and LMP and will be monitored using a wearable smart wristwatch that will track their daily sleep patterns and physical activity (LMP+ICTs).
Study: NCT03138681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphocreatine
Description: Phosphocreatine (1g) is given intravenously twice a day for 14 days
Study: NCT03029390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine
Description: Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg
Study: NCT00512980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine
Study: NCT03029390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal).
Study: NCT00104234

Intervention type: DRUG
Group type: OTHER
Intervention: N-acetylgalactosamine 4-sulfatase

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo/rhASB
Study: NCT00512980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinblastine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Study: NCT00053326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies
Study: NCT00512980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Study: NCT02371941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cromolyn sodium
Description: Oral cromolyn sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT03143452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine gel
Description: 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine eye drop
Description: 0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
Study: NCT00703534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule. administered as a single dose twice daily for 4 weeks
Study: NCT01966718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repository corticotropin injection
Description: An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
Study: NCT02865876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated Corneal Cross-linking
Description: All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
Study: NCT00703534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelusil®
Description: Chewable tablets taken as needed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gelusil®
Description: Chewable tablets taken as needed
Study: NCT01308515

Intervention type: DEVICE
Group type: OTHER
Intervention: Vanguard Knee System with AS Bearing
Description: FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
Study: NCT02865876

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Accelerated Corneal Cross-linking
Description: All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
Study: NCT01308515

Intervention type: DEVICE
Group type: OTHER
Intervention: Vanguard Knee System with PS Bearing
Description: FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
Study: NCT04092075

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF-utilizing powered toothbrush
Description: RF-utilizing Powered toothbrush

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control placebo with no RF
Description: Placebo control, toothbrush with no RF
Study: NCT04045002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'MyPinkMom' educational intervention
Description: The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session.
Study: NCT00764764

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder treatment
Description: shoulder exercise, joint mobilization, home program, posture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Shoulder AND cervical treatment
Description: Cervical and shoulder joint mobilization, exercise, posture, and home program
Study: NCT00284453

Intervention type: PROCEDURE
Intervention: Peripheral blood sampling
Description: blood samples will be collected within 72 hours of subjects receiving \>2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).

Intervention type: PROCEDURE
Intervention: Peripheral blood sampling
Description: blood samples will be collected within 72 hours of subjects receiving \>2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).

Intervention type: PROCEDURE
Intervention: Peripheral blood sampling
Description: blood samples will be collected within 72 hours of subjects receiving \>2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
Study: NCT02194465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally